Transcend Therapeutics

About Transcend Therapeutics

Transcend Therapeutics is dedicated to developing rapid-acting treatments for neuropsychiatric diseases, with a mission to create a world free from such conditions and to bring new mental health solutions to the 1 billion patients who need better options.

Products & Services

TSND-201:A rapid-acting neuroplastogen for the treatment of PTSD, showing promising results in clinical studies.

Specialties

Neuropsychiatric disease treatment Rapid-acting neuroplastogens PTSD treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1000000 MR: - FA: $1 million FAN: 1000000	D: 2023-09-21 FD: 2023-09-21	1 investors
2	RT: Series A T: - FT: Series A	A: 40000000 MR: - FA: $40 million FAN: 40000000	D: 2023-02-23 FD: 2023-02-23	4 investors

Grant Latest

2023-09-21

$1.0M

1 investor (Pro only)

Series A 2023-02-23

$40.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kevin Ryan

Co-founder and Chairman

LinkedIn (Pro only)

B

Blake Mandell

Co-founder and CEO

LinkedIn (Pro only)

B

Benjamin Kelmendi, MD

Co-founder and Chief Scientific Advisor

LinkedIn (Pro only)

M

Martin Stogniew, PhD

Chief Development Officer

A

Amanda Jones, PharmD

Sr. VP, Clinical Development

B

Barbara Rothbaum, PhD

Professor of Psychiatry, Director of the Trauma and Anxiety Research Program

View 6 more team members with Pro

Unlock Full Team Directory

Recent News